The city of Durham, North Carolina, currently has 2 active clinical trials seeking participants for Type 2 Diabetes research studies.
Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US
NCT05129345
Recruiting
This study has 3 aims. Aim 1: Identify social determinants of cardiometabolic health and determine facilitators and modifiable barriers in achieving treatment goals. Aim 2: Assess PLWH knowledge, skills, and confidence for self-management of cardiometabolic disorders. Aim 3: Tailor a self-management support and education intervention with stakeholder input to address barriers to achieving treatment goals for cardiometabolic disorders in PLWH at the study sites.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Duke University - Duke Study Site, Durham, North Carolina
Conditions: Hypertension, Dyslipidemias, Type 2 Diabetes, HIV-1-infection
Register for Updates
CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients
NCT04906213
Recruiting
CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to empagliflozin 10mg versus placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Kidney Transplant; Complications, Diabetes Mellitus, Type 2
Register for Updates